Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

@article{Bushby2010DiagnosisAM,
  title={Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management},
  author={Katharine M D Bushby and Richard S. Finkel and David J Birnkrant and Laura E. Case and Paula R Clemens and Linda Cripe and Ajay Kaul and Kathi Kinnett and Craig M. McDonald and Shree K Pandya and James Poysky and Frederic Shapiro and Jean L Tomezsko and Carolyn M. Constantin},
  journal={The Lancet Neurology},
  year={2010},
  volume={9},
  pages={77-93}
}
Duchenne muscular dystrophy (DMD) is a severe, progressive disease that affects 1 in 3600-6000 live male births. Although guidelines are available for various aspects of DMD, comprehensive clinical care recommendations do not exist. The US Centers for Disease Control and Prevention selected 84 clinicians to develop care recommendations using the RAND Corporation-University of California Los Angeles Appropriateness Method. The DMD Care Considerations Working Group evaluated assessments and… 
Diagnosis and management of Duchenne muscular dystrophy, part 2: respiratory, cardiac, bone health, and orthopaedic management
TLDR
The new care considerations acknowledge the effects of long-term glucocorticoid use on the natural history of DMD, and the need for care guidance across the lifespan as patients live longer.
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
TLDR
A comprehensive set of DMD care recommendations for management of rehabilitation, orthopaedic, respiratory, cardiovascular, gastroenterology/nutrition, and pain issues, as well as general surgical and emergency-room precautions are presented.
Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management
TLDR
Care considerations for diagnosis of DMD and neuromuscular, rehabilitation, endocrine (growth, puberty, and adrenal insufficiency), and gastrointestinal (including nutrition and dysphagia) management are presented.
The respiratory management of patients with duchenne muscular dystrophy: A DMD care considerations working group specialty article
TLDR
This document represents the consensus recommendations of the project's 10‐member Respiratory Panel and includes advice on necessary equipment, procedures and diagnostics; and a structured approach to the assessment and management of the respiratory complications of DMD via assessment of symptoms of hypoventilation and identification of specific thresholds of forced vital capacity, peak cough flow and maximum expiratory pressure.
Interpretation of "Diagnosis and management of Duchenne muscular dystrophy: a guide for families (2011 version)"
TLDR
This guideline is recommended as the first choice by TREAT- NMD for DMD diagnosis and care and covers diagnostics, steroid treatment, rehabilitation, orthopedics, pulmonary, cardiac, gastrointestinal, psychosocial, surgical and emergency management of DMD.
Imperatives for DUCHENNE MD: a Simplified Guide to Comprehensive Care for Duchenne Muscular Dystrophy
TLDR
A one-page document has been generated from published care recommendations, summarizing the key elements of comprehensive care for people living with DMD (“Imperatives for Duchenne muscular dystrophy”), and was developed through an international collaboration between Parent Project Muscular Dystrophy (PPMD), United Parent Projects Muscular dystropy (UPPMD) and TREAT-NMD.
Current management of Duchenne muscular dystrophy in the Middle East: expert report
TLDR
Different aspects of the current management of DMD in the Middle East, north Africa (MENA) region are addressed, and experts’ recommendations on how to optimally diagnose and treat patients suffering from this disease are gathered.
Diagnosis and management of Duchenne muscular dystrophy
  • P. Baxter
  • Medicine
    Developmental medicine and child neurology
  • 2010
TLDR
A largely North American group of 84 experts in different aspects of care were commissioned by the US Centers for Disease Control and Prevention to form panels to reviewe available evidence and where this was lacking they used the ‘RAM’ method to reach conclusions, which is a very impressive overview.
Diagnosis and management of Duchenne muscular dystrophy, part 3: primary care, emergency management, psychosocial care, and transitions of care across the lifespan
TLDR
Assessments and interventions that are designed to improve mental health and independence, functionality, and quality of life in critical domains of living, including health care, education, employment, interpersonal relationships, and intimacy are discussed.
Recent developments in the management of Duchenne muscular dystrophy
TLDR
The multi-systemic features of DMD require multidisciplinary team working, where paediatricians play an essential role in the management of patients, from diagnosis to planned transition into adult medical services.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 320 REFERENCES
Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders
  • J. Bourke
  • Medicine
    Developmental medicine and child neurology
  • 2006
TLDR
Most cardiologists are unfamiliar with the nature of cardiac involvement in Duchenne muscular dystrophy and its management, and concerns about possible side effects seem to dominate therapeutic decisions in DMD, perhaps because of its more obvious outward manifestations.
Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care
TLDR
A comprehensive set of DMD care recommendations for management of rehabilitation, orthopaedic, respiratory, cardiovascular, gastroenterology/nutrition, and pain issues, as well as general surgical and emergency-room precautions are presented.
Exploring chronic pain in youths with Duchenne Muscular Dystrophy: a model for pediatric neuromuscular disease.
TLDR
D Duchenne Muscular Dystrophy (DMD), the most common NMD of childhood, is used as an informative model to explore the complexities of chronic pain in children with NMD.
Practice Parameter: Corticosteroid treatment of Duchenne dystrophy
Background: The Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society develop practice parameters as strategies for patient
Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy
TLDR
It is demonstrated here that steroid treatment, begun prior to ventricular dysfunction retards the anticipated development of ventricularfunction, and treatment with steroids was protective against Ventricular dysfunction.
The role of corticosteroids in Duchenne muscular dystrophy: a review for the anesthetist
TLDR
This review will focus on the role of corticosteroids and their implications for anesthetic management in DMD.
The role of corticosteroids in muscular dystrophy: A critical appraisal
TLDR
The therapeutic value of corticosteroid drugs in Duchenne muscular dystrophy is limited, but these drugs represent the best treatment option currently available.
Developmental progress in Duchenne muscular dystrophy: lessons for earlier detection.
  • E. Parsons, A. Clarke, D. Bradley
  • Medicine
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society
  • 2004
TLDR
The identification and implementation of an effective screening tool to reduce diagnostic delay is more complex than previously portrayed and service providers need to ask whether newborn screening is the only feasible solution to diagnostic delay.
Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention
TLDR
A Muscular Dystrophy Campaign funded workshop to look into the potential problems of osteoporosis occurring in boys with DMD treated with steroids, to assess the adverse effects of corticosteroid (steroid) treatment relating to bone mineral density and longitudinal growth and to assessThe current evidence for the prevention and treatment of osteeporosis.
Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy
TLDR
Although boys with Duchenne muscular dystrophy on long-term corticosteroid treatment have a significantly decreased risk of scoliosis and an extension of more than 3 years' independent ambulation, they are at increased risk of vertebral and lower limb fractures compared with untreated boys.
...
1
2
3
4
5
...